as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹329.9
Change
-18.15 (-5.21%)
Open
₹349.8
Prev. Close
₹348.05
Day High
₹349.8
Day Low
₹329.4
Volume Analysis
Traded
95,969
Delivered
56,695
Delivery %
59.08%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (33.0%)
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year EPS growth (60.0%)
- •Strong 3-year revenue growth (17.7%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹363.74 | ₹356.77 | ₹343.34 | ₹336.37 | ₹322.94 | ₹315.97 | ₹302.54 |
| Fibonacci | ₹356.77 | ₹348.98 | ₹344.16 | ₹336.37 | ₹328.58 | ₹323.76 | ₹315.97 |
| Camarilla | ₹335.51 | ₹333.64 | ₹331.77 | ₹336.37 | ₹328.03 | ₹326.16 | ₹324.29 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+20.78%
1 Week
-3.26%
1 Month
+13.78%
3 Months
+1.26%
6 Months
+5.33%
1 Year
+9.51%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹85.85
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
13.44%
Net margin 11.85% × asset turnover 0.6x × equity multiplier 1.89x
Company Overview
Sector
Healthcare
Market Cap
₹1,780 Cr
P/E (TTM)
42.6
ROE
14.2%
Book Value
₹53.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Suraksha Diagnostic Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 67/100. The strongest factor is Growth (93/100), while Valuation (13/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (33.0%). FII holding has been falling.
TopFund Score — Fundamentals Quality
67/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has delivered good profit growth of 31.8% CAGR over last 5 years
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Audio recording of November 13, 2026 earnings call for Q2 and H1 FY27 is now available.
Investor Presentation for Quarter and Half Year ended 30 September 2026 Q2 FY 2026-27
Suraksha issued corrigendum to Q2/H1 FY27 results; corrected tests, patients and revenue metrics.
Corrigendum revises headline to total income over ₹100 crore and Q2 net profit to ₹15 crore.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 60 | 52 | 55 | 61 | 67 | 60 | 65 | 73 | 79 | 78 | 81 | 88 | 99 |
| Expenses + | 39 | 36 | 36 | 40 | 44 | 41 | 46 | 49 | 55 | 55 | 57 | 57 | 64 |
| Operating Profit | 21 | 15 | 19 | 21 | 23 | 18 | 19 | 24 | 24 | 23 | 24 | 30 | 35 |
| OPM % | 35.0% | 30.0% | 35.0% | 34.0% | 35.0% | 31.0% | 29.0% | 33.0% | 31.0% | 30.0% | 30.0% | 35.0% | 35.0% |
| Other Income + | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 5 |
| Depreciation | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 10 | 11 | 11 | 11 | 13 |
| Profit before tax | 11 | 6 | 9 | 11 | 14 | 8 | 9 | 12 | 12 | 10 | 10 | 17 | 19 |
| Tax % | 24.0% | 27.0% | 32.0% | 27.0% | 26.0% | 26.0% | 22.0% | 26.0% | 27.0% | 28.0% | 38.0% | 22.0% | 21.0% |
| Net Profit + | 8 | 5 | 6 | 8 | 10 | 6 | 7 | 9 | 9 | 7 | 6 | 13 | 15 |
| EPS in Rs | 2 | 1 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 3 | 3 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | 11 | 15 | 18 | 20 | 18 | 31 | 25 | 21 | 26 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 158 | 140 | 223 | 190 | 219 | 252 | 310 | 346 |
| Expenses + | 123 | 115 | 174 | 143 | 146 | 170 | 214 | 233 |
| Operating Profit | 34 | 25 | 49 | 47 | 73 | 82 | 96 | 113 |
| OPM % | 22.0% | 18.0% | 22.0% | 25.0% | 33.0% | 33.0% | 31.0% | 33.0% |
| Other Income + | 2 | -1 | 1 | 1 | 1 | 4 | 3 | 4 |
| Interest | 2 | 2 | 2 | 10 | 10 | 9 | 13 | 16 |
| Depreciation | 13 | 16 | 15 | 32 | 33 | 35 | 41 | 46 |
| Profit before tax | 21 | 6 | 33 | 7 | 31 | 41 | 45 | 55 |
| Tax % | 28.0% | -1.0% | 28.0% | 10.0% | 26.0% | 25.0% | 30.0% | — |
| Net Profit + | 15 | 6 | 24 | 6 | 23 | 31 | 31 | 41 |
| EPS in Rs | 4 | 1 | 6 | 2 | 5 | 6 | 6 | 8 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.0% | — |
| Sales growth | — | -11 | 59 | -15 | 15 | 15 | 23 | 25 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Reserves | 111 | 118 | 141 | 147 | 171 | 201 | 234 | 266 |
| Borrowings + | 13 | 18 | 21 | 99 | 92 | 89 | 130 | 155 |
| Other Liabilities + | 42 | 28 | 32 | 28 | 30 | 33 | 73 | 89 |
| Total Liabilities | 173 | 171 | 201 | 281 | 300 | 334 | 448 | 521 |
| Fixed Assets + | 128 | 119 | 119 | 195 | 212 | 223 | 315 | 381 |
| CWIP | 0 | 0 | 1 | 2 | 1 | 11 | 37 | 17 |
| Investments | 5 | 5 | 0 | 0 | 0 | 1 | 0 | 0 |
| Other Assets + | 39 | 46 | 80 | 84 | 87 | 99 | 97 | 123 |
| Total Assets | 173 | 171 | 201 | 281 | 300 | 334 | 448 | 521 |
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 10 | 10 | 10 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 31 | 24 | 42 | 44 | 60 | 63 | 82 |
| Cash from Investing Activity + | -20 | -28 | -44 | -21 | -35 | -40 | -52 |
| Cash from Financing Activity + | -10 | 3 | 1 | -24 | -25 | -24 | -29 |
| Net Cash Flow | 1 | -1 | 0 | -1 | 0 | 0 | 1 |
| Free Cash Flow | 15 | 8 | 23 | 32 | 18 | 21 | 15 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 111 | 100 | 95 | 109 | 95 | 90 | 99 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Public | 15.39% | 14.71% | 14.79% | 15.3% | 14.98% | 14.31% | 14.2% | 15.37% |
| Promoters | 48.78% | 48.78% | 48.89% | 48.98% | 49.0% | 49.1% | 49.1% | 49.1% |
| FII | 15.39% | 14.46% | 13.95% | 13.73% | 13.46% | 13.46% | 13.47% | 13.98% |
| DII | 20.43% | 22.05% | 22.37% | 21.98% | 22.57% | 23.14% | 23.22% | 21.56% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Suraksha Diagnostic Ltd (this stock) | 1,780 | 42.6 | 6.45 | 14.2% |
| Ngl Fine Chem Limited | 1,783 | 27.9 | 4.92 | 17.4% |
| Tarsons Products Limited | 1,678 | 205.0 | 2.65 | 2.44% |
| Krsnaa Diagnostics Ltd | 1,661 | 16.9 | 1.6 | 10.9% |
| Syncom Formu (i) Ltd | 1,907 | 20.0 | 4.06 | 17.6% |
| Fischer Medical Venture L | 1,642 | 144.0 | 3.52 | 8.91% |
| Beta Drugs Limited | 1,990 | 38.3 | 4.54 | 18.8% |
Which Mutual Funds Hold Suraksha Diagnostic Ltd?
Frequently Asked Questions about Suraksha Diagnostic Ltd
Suraksha Diagnostic Ltd (SURAKSHA) closed at ₹329.9 on NSE on 19 November 2026, down 18.15 (5.21%) from the previous close.
Suraksha Diagnostic Ltd trades on the NSE (National Stock Exchange of India) under the symbol SURAKSHA.
Suraksha Diagnostic Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 42.6.
Suraksha Diagnostic Ltd has a dividend yield of 0.15%.
Suraksha Diagnostic Ltd's 52-week high is ₹384.0 and its 52-week low is ₹224.0.
Suraksha Diagnostic Ltd has a market capitalisation of ₹1,780 crore.
Suraksha Diagnostic Ltd has a TopFund Quality Score of 67/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Suraksha Diagnostic Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.